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Abstract
Background: Alcohol dependence affects approximately 3% of the English population, and accounts for significant
medical and psychiatric morbidity. Only 5.6% of alcohol-dependent individuals ever access specialist treatment and
only a small percentage ever seek treatment. As people who are alcohol dependent are more likely to have
experienced health problems leading to frequent attendance at acute hospitals it would seem both sensible and
practical to ensure that this setting is utilised as a major access point for treatment, and to test the effectiveness of
these treatments.
Methods/Design: This is a randomised controlled trial with a primary hypothesis that extended brief
interventions (EBI) delivered to alcohol-dependent patients in a hospital setting by an Alcohol Specialist Nurse
(ASN) will be effective when compared to usual care in reducing overall alcohol consumption and improving
on the standard measures of alcohol dependence. Consecutive patients will be screened for alcohol misuse in
the Emergency Department (ED) of a district general hospital. On identification of an alcohol-related problem,
following informed written consent, we aim to randomize 130 patients per group. The ASN will discharge to
usual clinical care all control group patients, and plan a programme of EBI for treatment group patients.
Follow-up interview will be undertaken by a researcher blinded to the intervention at 12 and 24 weeks. The
primary outcome measure is level of alcohol dependence as determined by the Severity of Alcohol
Dependence Questionnaire (SADQ) score. Secondary outcome measures include; Alcohol Use Disorders
Identification Test (AUDIT) score, quantity and frequency of alcohol consumption, health-related quality of life
measures, service utilisation, and patient experience. The trial will also allow an assessment of the cost-
effectiveness of EBI in an acute hospital setting. In addition, patient experience will be assessed using
qualitative methods.
Discussion: This paper presents a protocol for a RCT of EBI delivered to alcohol dependent patients by an ASN
within an ED. Importantly; the trial will also seek to understand patients’ perceptions and experiences of being part
of a RCT and of receiving this form of intervention.
Trial registration number: ISRCTN: ISRCTN78062794
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Scale of alcohol dependence in acute hospitals
A wide range of harms can ensue from risky drinking
behaviour [1] many of which have to be dealt with by
general hospitals on a daily basis. Alcohol is a factor in
over 40 medical conditions that can lead to hospitalisa-
tion, which in 2010/11 accounted for 1.1 million hospi-
tal admissions in England, an increase of 12% compared
with 2008/09 [2,3]. This figure does not include the 12%
of ED attendances that are attributed to alcohol, which
increases to 70% at peak times [4]. Additionally, preva-
lence of alcohol dependence in medical inpatients
ranges from 3% to 47% [5,6]. Furthermore, over the past
two decades, alcohol-related death rates have doubled
[7]. The resulting annual cost to the UK NHS has been
estimated at between £2 and £3 billion [8,9]. A rigorous
assessment of alcohol-related harm showed that 38% of
men and 16% of women (aged 16-64 years) have an
alcohol use disorder, equating to approximately to 8.2
million people in England [10]. Of most concern is the
estimate that 3-5% of the population in England (1.1
million people) are dependent on alcohol. However,
treatment in acute settings would seem to be woefully
inadequate, as in most cases alcohol dependent hospita-
lised patients are given pharmacological detoxification
and, when stable, discharged into primary care without
further treatment or support. This is a missed opportu-
nity on several levels: early identification and treatment
can reduce subsequent individual harm, and may pre-
vent desease pregression, which will ultimatly reduce
the overall burden of alcohol to society as a whole and
the NHS in particular.
Evidence for effectiveness of treatment in acute care
settings
When considering brief intervention (BI) as a treatment
approach for alcohol dependence in an acute care set-
ting, it is important to note that the intensity of inter-
vention does not seem to be a predictor of treatment
effectiveness [11-15]. For that reason, brief treatments
may be as effective as more intensive treatments in
some patient groups. It is therefore noteworthy that, for
those patients who are dependent on alcohol, treatments
that are brief, timely and pragmatic have received little
research focus. Furthermore, the assessment of the
effectiveness of treatment is complex; particularly since
between 12 to 35% of patients recover with little or no
specialist intervention, a phenomenon described as “nat-
ural recovery” [16-19]. It has also been established that
irrespective of their similarities and differences treat-
ments seem to perform equally well, or badly [20,21].
It is well established that brief treatments are effective
for hazardous and harmful drinkers [22] but may also
have some efficacy in alcohol-dependent patients
[22-30]. However, BI as a treatment option in acute hos-
pitals has yet to be systematically tested in dependent
drinkers [31-34]. The ED has been shown to be an
appropriate setting in which to identify non-treatment
seeking hazardous and harmful drinkers [31,35], and is
potentially best placed to deliver effective care based on
a BI approach [22,23,25-29,35,36]. However, to date,
there has been little focus on the effectiveness of BI in
alcohol dependence. A pragmatic non-randomised con-
trolled study (Quaisi-experimental) of BIs by ASNs
showed that 30% of alcohol-dependent patients’ main-
tained abstinence for 6 months post treatment [37]. A
subsequent study showed that patients treated by the
ASN had significantly shorter stay in hospital and a
significant reduction in alcohol consumption and
dependence at 6 months [38]. Furthermore, a recent
retrospective evaluation found that alcohol dependent
patients realised as much benefit as non-dependent
patients from BIs delivered by an ASN in acute care
[35].
Given the scale of the problem, and the lack of choice
currently available for this group of patients, it is vital to
develop novel models of care which focus on the deliv-
ery of effective treatments in the acute care setting
where this patient group most frequently presents.
Indeed, Saitz proposed that enhanced brief intervention
strategies may be effective in decreasing the direct com-
plications associated with unhealthy alcohol use [11,39].
Methods/Design
Hypothesis
EBIs delivered to alcohol-dependent patients in a hospi-
tal setting by an ASN will be effective when compared
to usual care in reducing overall alcohol consumption
and improving on the standard measures of alcohol
dependence.
Overall aim of the study
To test the clinical and cost effectiveness of extended BI
for individuals with alcohol dependence in an acute hos-
pital setting.
The study objectives are:
1. To determine whether BI reduces overall alcohol
consumption.
2. To determine whether BI is effective in the treat-
ment of alcohol dependence.
3. To determine whether BI reduces the length of stay
in hospital
4. To determine how patients feel about being
approached in an opportunistic manner for screening
for alcohol-related problems and subsequently being
asked to be part of a research trial.
5. To determine the cost effectiveness of BI for alcohol
dependence
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Page 2 of 9The study is a randomized controlled trial. The study
has been approved by North West Research Ethics
Committee ref: 09/H1005/61, and is fully compliant
with the Helsinki declaration 2008.
Setting
The trial will be conducted within an acute NHS Hospi-
tal Trust with an ED based within the North West
region of England. In order to minimise the risk of con-
tamination from other alcohol interventions, the setting
currently has no protocols for screening or advice within
their ED or hospital wards.
Design
The trial comprises three parts: the first is a test of the
clinical effectiveness of the EBI, the second is an assess-
ment of the patient’s experience of the intervention
using qualitative methods, while the third is an assess-
ment of cost effectiveness of the BI.
Blinding
The nature of delivery of EBI precludes blinding of sub-
jects. However, the nurses conducting the follow-up
assessments at 12 weeks and 6 months remain blinded
to treatment allocation. The statistician involved in data
analyses will be blinded for treatment allocation.
Trial inclusion and exclusion criteria
Trial inclusion and exclusion criteria have been selected
to ensure that patients are able to understand the
importance of adherence to the trial protocols, and are
able to provide contact details for follow-up. It is also
important to ensure that patients’ medical co-morbidity
will not necessitate long term hospitalisation, as this will
prevent the delivery of EBI as an out-patient. Further-
more, to prevent contamination by other treatments the
patient must not have been involved in any alcohol-spe-
cific treatment for alcohol dependence in the previous 6
months.
All ED attendees over the age of 17 years, with a score
equal to or greater than 16 on the AUDIT screening
tool, who live within the local area and are amenable to
attend follow-up clinics for interventions, are eligible.
Trial Recruitment Process (See flow diagram Figure 1)
Clinicians performing treatment or triage within the ED
will utilise their clinical examination to determine the
likelihood of the admission being alcohol-related. On
identification or suspicion of an alcohol-related problem,
the clinician will refer to the ASN for further assess-
ment. The ASN will also visit the ED and Medical
Assessment Unit daily to identify cases. The ASN will
then screen all patients using the AUDIT screening tool.
An AUDIT score of 16 and above will be considered a
positive screen. Patients will then be assessed against
inclusion/exclusion criteria.
Trial consent procedure
All eligible patients will be given relevant verbal and
written information about the research and asked to
consent. Due to the opportunistic nature and design of
the study, patients will be asked to provide written con-
sent on initial assessment. This is to ensure that the
population recruited is representative of the clinical
population attending ED whether aware or unaware of
the role of alcohol in their presentation. Patients will be
able to withdraw from the study at any point. If reasons
for opting out are volunteered by the patient, we will
ask consent to use this information. The ASN will be
the nurse taking consent from the patient and will dis-
cuss with the patient’s named nurse if they agree that
the patient is physically and mentally fit to give consent
to the study. The patient will be provided with a patient
information leaflet (PIL) which the nurse will discuss in
detail. If the patient gives consent, they will undergo a
comprehensive assessment at which the ASN will collect
all baseline demographic data, information on co-mor-
bidity, complete all screening tools, and take a full alco-
hol history. Those patients unwilling to consent to
Identification of Case 
Referral to ASN 
Screening for Inclusion/exclusion criteria  
Exclusion criteria apply  
EXCLUDE 
Inclusion criteria apply 
Happy to consent to randomization 
NO 
YES 
Envelope Randomisation 
Treatment 
Group 
Control  
Group 
Figure 1 Trial Recruitment Process.
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asked to consider consent for their demographic data to
be collected, and will be asked if they wish to take part
in the qualitative part of the study. A separate PIL will
be used for the qualitative analysis, who will then be
interviewed by the qualitative researcher (QR).
Trial randomization procedure
Following consent, the research nurse will complete the
screening and diagnostic tools:
a) Severity of Alcohol Dependence Questionnaire
(SADQ),
b) Leeds Dependency Questionnaire (LDQ),
c) Readiness to Change Questionnaire (RCQ), and
d) EuroQoL EQ-5D.
The patient will then be randomized to either the
intervention or control group by the research nurse.
Patients will be randomized using sequentially num-
bered opaque sealed envelopes prepared according to a
computer-generated randomisation allocation sequence.
Block randomisation using randomly varying block sizes
(prepared using Stata version 8.2) will ensure equal
numbers of patients are recruited into each group. Ran-
domisation services will be provided by an independent
statistician at the Clinical Trials Research Centre, Uni-
versity of Liverpool.
Data collection/management process
Intervention
All data will be collected prospectivley utilising a Case
Report Form (CRF). Data will be collected at baseline
and each follow-up point. Data from the CRF which will
carry only an anonymised number will be entered
directly on a MACRO™ electronic database system.
Patient information will be kept on a patient log, which
will remain in a locked filing cabinet in a clinical room
at the clinical site, alongside the anonymised case report
files.
Qualitative
Interviews will be digitally recorded, anonymised and
transcribed by a third party. All digital files will be
destroyed within 12 weeks of interview. NVivo, compu-
ter assisted qualitative data analysis software that stores
and retrieves data will be used.
Economic
For retreval of hospital utilisation data, researchers will
use hospital based electronic recording systems. For GP
data, the researchers will visit individual patient GP sur-
geries and collect data from case files and electronic sys-
tems. Ambulance data will be collected electronically.
All data will be entered onto the CRF, and will be
entered directly in to a MACRO™ electronic database
system.
Primary outcome measures
As in previous research by our team, the primary out-
come measure for the study is the change in SADQ
score at 6 months post randomisation. The SADQ is a
short 20-item questionnaire designed to measure sever-
ity of dependence on alcohol [40]. There are five sub-
scales with four items in each: Physical Withdrawal,
Affective Withdrawal, Withdrawal Relief Drinking, Alco-
hol Consumption, and Rapidity of Reinstatement. Each
item is scored on a 4-point scale, ranging from “Almost
Never” to “Nearly Always” resulting in a corresponding
score of 0 to 3. Thus the total maximum score possible
is 60 and the minimum is 0.
Secondary outcome measures
The secondary outcome measures are:
1. A change in AUDIT score from baseline at 12
weeks and at 6 months post randomisation. Although
AUDIT is a screening test for alcohol use disorders [41],
in common with other studies, we will in this context
use it as both an outcome measure and a pre-screen to
establish presence of alcohol dependence. The sum of
the items scored has been used in several studies to
indicate dependence and therefore will allow for com-
parability with other trial baseline and outcome mea-
sures [10].
2. Measure of alcohol dependence utilising the Leeds
Dependency Questionnaire (LDQ) [42] at baseline, 12
weeks and 6 months post randomisation. The LDQ is a
10-item questionnaire designed to measure dependence
upon a variety of substances including alcohol. The
questionnaire includes 1 item from 10 markers that
define dependence; these include pre-occupation, sal-
ience of alcohol, compulsion to start, planning around
alcohol consumption, maximize effect, narrowing of use
of repertoire, compulsion to continue, primacy of effect,
constant state and cognitive set. Each item is scored 0-
1-2-3, giving a maximum of 30 with higher score indi-
cating greater degree of dependence.
3. Quantity and frequency of alcohol consumption in
UK units per drinking day at baseline, 12 weeks and 6
months post randomisation.
4. Readiness to Change Questionnaire (RCQ) at base-
line, 12 weeks and 6 months post randomisation. This is
an important measure for non-treatment seeking popu-
lations as it has been demonstrated that treatment-seek-
ing is an indication of treatment readiness, which has
been seen as important in achieving treatment outcomes
[20]. Using this measure will help us to investigate if
treatment readiness does indeed have any bearing on
treatment outcome in the population and setting.
5. Number of ED attendances 6 months pre and 6
months post treatment/control.
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months pre and 6 months post randomisation.
7. Number of hospital admissions 6 months pre and 6
months post randomisation.
8. Length of stay for initial treatment in days.
9. Biochemical indicators of co-morbid conditions
including Gamma-glutamyl transferase (GGT), Alanine
aminotransferase (ALT) and mean corpuscular volume
(MCV), when available will be extracted from a recent
laboratory records; this is defined as the last available
value prior to randomization.
Sample Size calculation
Based on a previous study by ourselves on dependent
drinkers receiving interventions from an ASN, it is
expected that 55% of such patients will display a fall in
SADQ score between baseline and 12 weeks’ follow up
[38]. Another confounder in this area of research is the
phenomenon of natural recovery (NR). The NR rate
over this time period expected in the control group is
expected to be no more than 25% (the literature ranges
from 12% with a treatment population [40] up to 35%
within a general lifetime population [43,44]). In order to
detect this difference between the groups (55% vs. 25%)
with 90% power at the 5% significance level, approxi-
mately 65 patients are required in each group. In order
to allow for an estimated 50% drop out rate (observed
in previous studies in similar patients), 130 patients will
be recruited per group. It is estimated that at least 5 eli-
gible patients will be recruited per week, and thus this
target should be achieved within the 12 month recruit-
ment period.
A fall in SADQ at 6 months is be the primary outcome.
As there were few studies that report SADQ scores at
baseline and follow-up, the revised power calculation was
based on the our own studies that 22% vs 53% fall in
SADQ between control and Intervention arms at 6
months. In order to detect this difference between the
groups (55% vs. 25%) with 90% power at the 5% signifi-
cance level, the required size is 103 (51 per group), and
206 (103 per group) once adjusted for 50% dropout.
Part A-Treatment group
Patients will receive an initial assessment and EBI from
the ASN. The EBI can best be described as a motiva-
tional approach to helping individuals change their
drinking behaviour. The intervention builds upon meth-
ods utilised to deliver BIs. However, as the intervention
is delivered for approximately 20 minutes on up to six
occasions the term “brief” is somewhat anomalous. We
will therefore refer to this mode of delivery as an
“extended brief intervention” (EBI). The intervention
will be delivered utilising the FRAMES approach [25],
and will be protocol driven with regular clinical supervi-
sion and observation to maximise intervention integrity.
Each intervention will be documented and timed. The
most important element of this model is the exploration
of patients’ p e r c e p t i o n sa st ot h el i n kb e t w e e nt h e i r
alcohol consumption and presentation. The FRAMES
[45] approach consists of the following:
FEEDBACK about personal risk or impairment;
RESPONSIBILITY: emphasis on personal responsibil-
ity for change;
ADVICE to cut down or abstain if indicated because
of severe dependence or harm;
MENU of alternative options for changing drinking
pattern and, jointly with the patient, setting a target;
EMPHATIC INTERVIEWING: listening reflectively
without cajoling or confronting; exploring with patients
the reasons for change as they see their situation;
SELF EFFICACY: an interviewing style that enhances
peoples’ belief in their ability to change.
A maximum of six treatment sessions, lasting 20 min-
utes each, will take place within the 12 week treatment
period (2 hours in total). Follow-up visits will be sched-
uled 12 weeks and 6 months following recruitment into
the study, and will be performed in the outpatients
department, at home or by telephone. The assessor will
be blinded to treatment allocation.
Control group
The control group will receive the same assessments as
the intervention group but they will not receive the EBI.
They will receive normal clinical care, which may or
m a yn o ti n c l u d er e f e r r a lt oaspecialist alcohol service.
Follow up visits will be arranged 12 weeks and 6 months
following recruitment into the study, either in outpati-
ents, at home or by telephone by a nurse researcher
blinded to treatment group.
Patient experience
The qualitative researcher (QR) conducting face-to-face
interviews will receive contact information for patients
consenting to this part of the trial. The QR will contact
the patient to arrange a time and place for the interview.
The patient experience part of the trial adopts a qualita-
tive design and will focus on gaining the patient’sv i e w s
on three main features of the study: a) of being screened
for alcohol-related problems,b )o fb e i n gi n v i t e dt ot a k e
part in a treatment programme, c) of being randomized.
It is designed to capture the patient’se x p e r i e n c ea n d
more particularly the opportunistic nature by which they
will have their drinking assessed and of their participa-
tion in the RCT. In-depth face to face interviews will be
used to collect data using a topic guide. The topic guide
is designed to elicit information about the following:
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screening.
▪ The experience of being offered and receiving a
BI.
▪ The experience of being identified as alcohol
dependent without being included in the interven-
tion arm of the study.
The identification of themes and patterns in the inter-
view data, using such techniques as constant compara-
tive and deviant case analysis, will be the predominant
method of organising, coding and categorizing the data.
Economic Evaluation
For the economic analysis, Euroqol EQ 5D [46] will be
utilised. EQ-5D is a standardised instrument for use as a
measure of health outcome. The first part of the EQ-5D
has 3-levels consisting of 5-dimensions including mobi-
lity, self care, usual activities, pain/discomfort, and anxi-
ety/depression. The second part is a visual analogue
scale (VAS) used by the patient to subjectively measure
on a point interval scale their health status. Worst ima-
ginable health state is scored as 0 at the bottom of the
scale, and best imaginable health state is scored as 100
at the top.
The major part of the economic analysis will be a sim-
ple comparison of costs in the two arms, measuring the
costs of providing the services against any differences in
NHS costs between the two arms which might occur as
a result of decreased use of all other services (for exam-
ple, hospital reattendances, accidents, GP visits etc)
regardless of their relationship to the abuse of alcohol.
The perspective will be limited to that of the NHS. The
time frame will be over the six months follow-up time
of the study. The costs of the intervention will be as
identified in the study. The costs of the use of NHS ser-
vices (A/E or GP attendances, cost per bed day as an
inpatient) will be taken from standard NHS costs pub-
lished by the [47]. The total costs of NHS care for each
patient will be based on these costs and on the amount
of service utilisation data collected as outlined above. It
may be necessary to adjust the analysis if there are dif-
ferences in baseline SADQ or in comorbidities.
A separate analysis of NHS costs specifically for alco-
hol related services will need to be undertaken as a
reduction in NHS service use may only be seen in alco-
hol-related areas, especially in patients with severe
comorbidities. Whether a particular NHS intervention is
related to alcohol or to another cause will require judg-
ment, which will be undertaken by two clinical assessors
who are blind to patient allocation.
If the costs (especially total costs but also alcohol only
related costs, provided that non alcohol related costs are
equal) in the intervention arm are less than in the non-
intervention arm, then the economic case for the inter-
vention is made. If the costs in the intervention arm are
greater than in the non-intervention arm, it is necessary
to undertake a cost effectiveness study, with the same
time frame and perspective.
Follow Up Strategy
This population can be difficult to follow-up and loss to
follow-up in this setting has been reported as high as
48% [38]. Therefore, the research nurse will take an
address and telephone details for the patient or relative/
carer. The patient will also be asked to give permission
for the research team to contact their General Practi-
tioner (GP) to obtain additional data. To facilitate ease
of access for treatment and follow-up, patients will be
offered a range of follow-up options either in the hospi-
tal, on the telephone, or at home. Two weeks prior to
the follow-up appointment, the patient or other named
contact will be contacted to determine if they will be
attending their appointment. The day before their
appointment, patients will be contacted to remind them
that their follow-up appointment is due the next day. If
the patient is unable to be contacted, they will be sent a
letter asking them to contact the team in order to
a r r a n g ef o l l o w - u p .I ft h ep a t i e n ti su n a b l et ob ec o n -
tacted via telephone or fails to respond to a letter for
the 6 month follow-up appointment, the research nurse
will visit the patients home to determine a) if the patient
still resides at that address, and b) if the patient is still
willing to undertake a follow-up appointment. If the
patient cannot be contacted by the team at this stage,
they will be said to be lost to follow-up.
Ethical Considerations
Each group will receive normal clinical care in their
respective groups. No patient group will be disadvan-
taged as clinical care in these patients varies, and we do
not know which the most effective treatment is.
Planned Analysis
An intention to treat analysis (ITT) will be performed
on all analyses. This will include all patients assigned to
the two groups; EBI or standard care as randomised,
irrespective of the patient’s compliance with the study
protocol or the actual study intervention received. A per
protocol analysis will also be performed. The per proto-
col analysis will comprise all patients in the ITT popula-
tion who have met all the following major inclusion
criteria and who do not have any major protocol viola-
tion. A sensitivity analysis will be applied for any miss-
ing primary outcome data.
To ensure the appropriateness of the event rates used
in this sample size calculation, an internal pilot is
planned after 160 patients will have been randomised.
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are:
￿ Evaluation of overall proportion of patients dis-
playing a fall in SADQ score to compare the esti-
mate used in the original sample size calculation.
￿ Monitoring study recruitment and missing data for
all primary and secondary outcomes.
The only outcome data that will be analysed within
the internal pilot analyses is the proportion of patients
displaying a fall in the primary outcome of the study
(SADQ) between baseline and 12 weeks’ follow-up. The
results will be presented as numbers and percentages
and the proportion of patients showing a fall in SADQ
used in the original sample size calculation will also be
checked by using the estimates that are obtained from
the internal pilot analysis. Outcomes showing unex-
pected missing information will be highlighted and dis-
cussed with members of the Independent Trial Steering
Committee (ITSC). If sample size recalculation suggests
need for more patients to preserve power to detect
treatment effect, then on the advice of the ITSC, we will
aim to increase recruitment and consider implications
for funding and existing resources.
Analysis of primary outcomes
The primary endpoint is a fall in SADQ at 6 months
post randomisation. Test scores will be summarised
using descriptive statistics, means with 95% confidence
intervals (or medians with inter-quartile ranges if non-
normally distributed) at baseline, and 6 months. The
hypothesis of no difference between the two treatment
arms at 6 months (separate analyses) will be tested
using analysis of covariance (ANCOVA), controlling for
baseline measurements. A p-value of 0.05 (5% level) will
be used to declare statistical significance and 95% confi-
dence intervals of the estimated effects will be reported.
Time by treatment interaction will be assessed. The pri-
mary analysis using ANCOVA will not adjust for any
missing data. However, reasons for missing outcome
data will be reported and a sensitivity analysis will be
undertaken. The assumptions that are made when using
ANCOVA (i.e. normality of scores at treatment levels,
homogeneity of variance, homogeneity of regression
slopes, linear regression) will be assessed. If unequal var-
iances, nonlinearity and/or non-parallel slopes are pre-
sent, a suitable transformation of scores will be
employed to improve the linearity and to promote
equality of the variances.
Analysis of secondary outcomes
The AUDIT and AUDIT-C, LDQ and RCQ scores will
be summarised using descriptive statistics: means with
95% confidence intervals (or medians with inter-quartile
ranges if non-normally distributed) at baseline, 12 weeks
and 6 months. Change from baseline at 12 weeks and at
6 months post treatment will be presented. The hypoth-
esis of no difference between the two treatment arms at
12 weeks and 6 months (separate analyses) will be tested
using analysis of covariance (ANCOVA), controlling for
baseline measurements. A p-value of 0.05 (5% level) will
be used to declare statistical significance and 95% confi-
dence intervals of the estimated effects will be reported.
Time by treatment interaction will be assessed. This
analysis using ANCOVA will not adjust for any missing
data. However, reasons for missing outcome data will be
reported and a sensitivity analysis will be undertaken
Time by treatment interaction will be assessed. The
mean (standard deviation) or median (inter-quartile
range) of quantity and frequency of alcohol consumed
in UK units per drinking day will be computed depend-
ing on whether it is skewed or not, and compared across
treatment groups at 12 weeks and at 6 months post
treatment using a t-test or Mann Whitney U test. The
number of ED attendances is also similarly analysed.
Summaries of length of stay in hospital will be presented
as means (standard deviations) or medians (inter-quar-
tile ranges) depending on whether it is normally distrib-
uted or not, and compared across treatment groups.
Laboratory parameters will be summarized using means,
standard deviations, confidence intervals, and ranges.
Additional summaries of thed a t ai n c l u d e dp l o t so f
mean (±SE) values over time and scatter plots of pre-
vs. post-treatment values. Change from baseline and at
12 weeks and at 6 months post treatment will be pre-
sented. A formal test of a treatment-covariate interac-
tion will be conducted by including the interaction term
in a regression model. Exploratory analysis will be con-
ducted as to the impact on any treatment effect of other
f a c t o r ss u c ha sg e n d e ro ra g e .Ap - v a l u eo f0 . 0 5( 5 %
level) will be used to declare statistical significance and
95% confidence intervals of the estimated effects will be
reported.
Missing data and missing questionnaire items
To investigate how sensitive the results of the primary
and secondary analysis are to missing data a number of
strategies will be used including joint modelling as well
as imputing values for missing longitudinal scores at 12
weeks and 6 months. The results of the sensitivity ana-
lyses will be compared to assess the relative effect of
missing data on the conclusions of the primary and sec-
ondary analysis.
For a scale which is based upon a number of items, of
which one or more is missing, to investigate how sensi-
tive the results of the primary analysis are to missing
data a number of strategies will be used including a
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score for the missing items from the mean of those
items which are available and this mean is then used to
replace the two missing values. Missing scale scores will
also be imputed with worst-case value, with best-case
value and model-based imputation.
Analysis of patient experience
The qualitative study adopts an approach based on the
analytical principles of Grounded Theory. Themes and
patterns in the data are identified using constant com-
parative techniques and dataa r eo r g a n i s e di n t oc o d e s
and categories to enable theory to be developed at a
substantive level. While the constant comparative
method is associated with the principles of grounded
theory, comparison represents a central analytic process
in inductive qualitative analysis that seeks to derive con-
cepts from data. In analysis the researcher is as inter-
ested in ‘negative’, ‘deviant’ or ‘anomalous’ evidence as
the identification of patterns of response. In this sort of
analysis divergence provides an important way of
informing and modifying emergent conceptualisations
and explanation.
Analysis of Health Economic measures
The economic analysis is designed to determine cost
effectiveness for delivery of the clinical intervention pro-
tocol. This will include analysis of post intervention
healthcare utilisation, and standard measures of changes
in health status.
Discussion
This paper presents a protocol for a RCT of EBI deliv-
ered to alcohol dependent patients by an ASN within an
ED. Importantly; the trial will also seek to understand
patients’ perceptions and experiences of being part of a
RCT and of receiving this form of intervention. Deter-
mining the clinical and cost effectiveness of the inter-
vention will help inform service design and planning.
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